+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-23 Receptor Antagonist Market by Indication (Crohn's Disease, Psoriasis, Psoriatic Arthritis), Product (Guselkumab, Risankizumab, Tildrakizumab), Distribution Channel, Route Of Administration, Therapy Line, Patient Age Group - Global Forecast 2025-2030- Product Image
IL-23 Receptor Antagonist Market by Indication (Crohn's Disease, Psoriasis, Psoriatic Arthritis), Product (Guselkumab, Risankizumab, Tildrakizumab), Distribution Channel, Route Of Administration, Therapy Line, Patient Age Group - Global Forecast 2025-2030- Product Image
New

IL-23 Receptor Antagonist Market by Indication (Crohn's Disease, Psoriasis, Psoriatic Arthritis), Product (Guselkumab, Risankizumab, Tildrakizumab), Distribution Channel, Route Of Administration, Therapy Line, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6139308
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for the IL-23 Receptor Antagonist Market Dynamics and Strategic Imperatives in a Rapidly Evolving Biopharmaceutical Landscape

The burgeoning IL-23 receptor antagonist landscape has emerged as a critical frontier in immunotherapy, capitalizing on insights into cytokine signaling to address chronic inflammatory conditions. As research uncovers the pivotal role of the IL-23 axis in driving pathogenic immune responses, pharmaceutical innovators have rapidly advanced molecules targeting this receptor, setting the stage for a new era of targeted therapeutics. In this high-stakes environment, developers must reconcile the promise of superior efficacy against the need for safety, patient convenience, and cost-effective manufacturing.

Against this backdrop, decision-makers across biopharma enterprises, healthcare providers, and payers are navigating an increasingly intricate ecosystem. Regulatory bodies are refining approval pathways to balance expedited access with rigorous safety assessments, while patient advocacy groups are amplifying the demand for therapies that deliver durable remission with minimal adverse effects. Furthermore, strategic collaborations between biotech start-ups and established pharmaceutical companies have accelerated pipeline progression. By synthesizing these developments, industry leaders can better anticipate market entry hurdles, identify high-value partnerships, and align their research strategies with evolving clinical and commercial dynamics.

Charting the Fundamental Transformations Reshaping the IL-23 Receptor Antagonist Ecosystem Through Innovation and Patient-Centric Approaches

Scientific breakthroughs and technological advances have catalyzed transformative shifts in the IL-23 receptor antagonist field, reshaping clinical development pathways and commercial strategies. Enhanced target validation techniques, fueled by high-resolution structural biology and precision immunology tools, have sharpened the selection of lead candidates. Concurrently, manufacturing innovations-such as continuous bioprocessing and modular facility designs-have streamlined scale-up, reduced production timelines, and improved cost predictability.

Digital health platforms are playing an increasingly prominent role, enabling remote patient monitoring and adherence support that enrich real-world evidence and inform payers’ value assessments. Meanwhile, the advent of companion diagnostics and biomarkers is steering trials toward patient subpopulations most likely to benefit, thus optimizing the benefit-risk profile. On the regulatory front, agencies are emphasizing flexible design frameworks and adaptive licensing models, encouraging sponsors to integrate robust post-marketing surveillance and patient-reported outcomes. These converging trends underscore a fundamental pivot toward patient-centric, data-driven development strategies and partnerships that transcend the traditional boundaries of product innovation.

Assessing the Multidimensional Impact of United States 2025 Tariff Policies on the IL-23 Receptor Antagonist Value Chain and Supply Networks

Shifts in the United States’ trade landscape, particularly the implementation of 2025 tariffs, have introduced new complexities to the IL-23 receptor antagonist value chain. Raw material sourcing, often reliant on specialized active pharmaceutical ingredients, has felt the ripple effects of increased import duties and reconfigured supply agreements. In response, manufacturers are exploring regional supplier diversification and strategic stockpiling to mitigate the risk of cost inflation and bottlenecks.

Moreover, component manufacturing and fill-finish operations are undergoing reassessment as onshore capabilities gain appeal to circumvent tariff-related premiums and reduce lead times. Contract development and manufacturing organizations have adjusted their service offerings to emphasize geographic flexibility, enabling sponsors to pivot seamlessly between production sites. The net result is an industry undergoing supply chain realignment, where agility and resilience have become as critical as technological prowess. These shifts are further compounded by parallel policy initiatives aimed at strengthening domestic biotech manufacturing and encouraging foreign direct investment in specialized bioprocessing hubs.

Uncovering Critical Segmentation Insights Across Indication Product Distribution Channel Route Administration Therapy Line and Patient Age Groups

Insights derived from a multi-pronged segmentation lens reveal that the IL-23 receptor antagonist landscape varies significantly across clinical indications, product offerings, distribution channels, routes of administration, therapy lines, and patient demographics. When examining the market by indication across Crohn’s disease, psoriasis, psoriatic arthritis, and ulcerative colitis, distinct patterns emerge in terms of disease prevalence, treatment guidelines, and patient journey considerations. Each indication carries unique therapeutic objectives, from mucosal healing in inflammatory bowel disease to sustained skin clearance in dermatology applications.

Evaluation of leading products such as guselkumab, risankizumab, and tildrakizumab highlights differences in molecular design, dosing frequency, and immunogenicity profiles, which in turn influence physician adoption and patient preference. Distribution networks encompass hospital pharmacies-divided into government and private institutions-alongside chain and independent retail pharmacies, with specialty pharmacies playing a critical role in managing biologic dispensing. The choice between intravenous infusion and subcutaneous injection further informs deployment strategies, affecting site-of-care economics and patient convenience. Therapy line segmentation, spanning first through third line settings, underscores the evolving place of IL-23 antagonists within treatment algorithms, while adult and pediatric age groups present divergent safety and dosing considerations that demand tailored trial designs and educational initiatives.

Exploring Regional Nuances and Growth Drivers Spanning the Americas Europe Middle East Africa and Asia Pacific for IL-23 Antagonists

Regional dynamics in the IL-23 receptor antagonist domain are characterized by heterogeneity in regulatory frameworks, reimbursement landscapes, and healthcare infrastructure. In the Americas, robust clinical trial networks and well-established reimbursement pathways facilitate rapid patient access, yet payers increasingly demand real-world data to support long-term cost effectiveness. Collaborative initiatives among academic centers, community hospitals, and patient foundations are driving awareness campaigns, which in turn elevate adoption in both metropolitan and underserved regions.

Across Europe, the Middle East, and Africa, divergent regulatory environments necessitate adaptive launch strategies, balancing centralized approvals via multinational agencies with country-specific pricing negotiations. Specialty pharmacy services are evolving to support home administration programs, reflecting the broader shift toward decentralized care models. In the Asia-Pacific region, emerging markets exhibit growing demand for targeted therapies as healthcare spending and access expand, while developed markets like Japan and Australia demonstrate sophisticated tendering processes and value-based procurement mechanisms. These regional nuances underscore the imperative for tailored market entry plans that align with local stakeholder expectations and optimize channel partnerships across each territory.

Analyzing Pioneering Biopharma Stakeholders and Their Strategic Portfolios in the IL-23 Receptor Antagonist Arena Driving Innovation and Collaboration

A review of prominent biopharma stakeholders reveals a competitive landscape defined by strategic alliances, differentiated pipelines, and manufacturing capabilities tailored to IL-23 receptor antagonists. Established global players have leveraged their distribution networks and regulatory expertise to secure early market access, while emerging biotech firms are introducing next-generation molecules with novel mechanisms to address residual unmet needs in refractory patient populations.

Collaborations between biotechnology companies and contract development and manufacturing organizations underpin a flexible asset deployment model, enabling innovators to focus on clinical advancement while outsourcing complex process engineering tasks. Co-development agreements and licensing deals have become commonplace, reflecting a mutual recognition that shared risk allocation accelerates time-to-market. In parallel, companies are investing in label expansion studies and broader therapeutic indications, ensuring that their IL-23 assets remain competitive across diverse clinical settings. Intellectual property strategies, coupled with patent life-cycle management tactics, further delineate the commercial positioning of each molecule within an increasingly crowded field.

Implementing Strategic Roadmaps and Actionable Recommendations for Industry Leaders to Navigate Competition Policy and Accelerate IL-23 Antagonist Adoption

To thrive in the IL-23 receptor antagonist sector, industry leaders should prioritize agile supply chain architectures that incorporate regional manufacturing redundancies and alternative sourcing strategies. Investment in continuous manufacturing platforms and advanced analytics can reduce process variability and expedite scale-up, enabling sponsors to respond swiftly to tariff-induced cost fluctuations. Concurrently, organizations must deepen engagements with patient advocacy groups and key opinion leaders to co-create educational initiatives that bolster therapy adoption across both hospital and specialty pharmacy settings.

Strategic pricing frameworks should be developed with payer dialogue in mind, integrating real-world evidence generation plans and outcomes-based contracting models. Diversifying clinical development pathways through adaptive trial designs and biomarker-driven cohorts will enhance differentiation and support label expansions into additional indications and therapy lines. Partnerships with digital health companies can amplify patient adherence programs, yielding richer data to inform payer negotiations. By executing these recommendations in an integrated manner, biopharma stakeholders will be well-positioned to navigate policy shifts, manage competitive pressures, and accelerate the adoption of IL-23 antagonists in both adult and pediatric populations.

Detailing Rigorous Research Methodologies Combining Secondary Data Expert Consultations and Structured Analytical Frameworks for IL-23 Antagonist Insights

This research leverages a rigorous methodological framework that integrates comprehensive secondary data collection, expert interviews, and structured analytical techniques. Secondary sources include peer-reviewed journals, regulatory agency guidelines, corporate filings, and specialized industry reports to capture the latest scientific developments and market dynamics. In parallel, qualitative insights were gathered through in-depth discussions with key opinion leaders, clinical investigators, supply chain specialists, and payers to validate assumptions and enrich contextual understanding.

The analytical framework employs cross-segmentation analysis and comparative benchmarking to delineate opportunities and challenges across indications, products, channels, and regions. A triangulation approach-corroborating quantitative findings with qualitative perspectives-ensures that conclusions are robust and reflective of real-world complexities. Adherence to ethical research standards and data privacy regulations undergirds the process, guaranteeing that proprietary information is handled securely and stakeholder anonymity is preserved. Collectively, these methodological pillars provide a transparent and replicable basis for our insights into the IL-23 receptor antagonist landscape.

Synthesizing Core Insights and Strategic Imperatives to Elevate Decision-Making and Stakeholder Engagement in the IL-23 Receptor Antagonist Sector

In closing, the IL-23 receptor antagonist segment stands at the intersection of scientific innovation and complex market forces, offering both promise and challenges for stakeholders across the biopharma value chain. The evolving regulatory milieu, coupled with shifting trade policies and diversified patient needs, underscores the importance of adaptable strategies that integrate robust supply chain design, targeted clinical development, and stakeholder engagement.

By synthesizing segmentation analyses, regional assessments, and competitive benchmarking, this report illuminates key pathways for enhancing market access, optimizing therapeutic impact, and sustaining growth momentum. Whether navigating tariff-induced cost pressures or pursuing label expansions in emerging indications, industry participants are equipped with actionable intelligence to inform their strategic roadmaps. Ultimately, success in this dynamic landscape will hinge on collaborative innovation, data-driven decision making, and a relentless commitment to improving patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Crohn's Disease
    • Psoriasis
    • Psoriatic Arthritis
    • Ulcerative Colitis
  • Product
    • Guselkumab
    • Risankizumab
    • Tildrakizumab
  • Distribution Channel
    • Hospital Pharmacy
      • Government Hospital
      • Private Hospital
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
    • Specialty Pharmacy
  • Route Of Administration
    • Intravenous Infusion
    • Subcutaneous Injection
  • Therapy Line
    • First Line
    • Second Line
    • Third Line
  • Patient Age Group
    • Adults
    • Pediatrics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Limited
  • Almirall, S.A.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in clinical trial data supporting differential efficacy of IL-23 antagonists in psoriasis and Crohn’s disease
5.2. Increasing investment in next generation bispecific antibodies targeting IL-23 and IL-17 pathways
5.3. Emerging real-world evidence highlighting long-term safety profiles of IL-23 inhibitors in elderly patients
5.4. Strategic partnerships between pharmaceutical companies and biotech firms accelerating IL-23 antagonist development
5.5. Market entry of biosimilars for existing IL-23 receptor antagonists driving pricing pressure dynamics
5.6. Regulatory approvals for expanded IL-23 antagonist indications in ulcerative colitis and ankylosing spondylitis
5.7. Advances in targeted delivery technologies improving subcutaneous administration of IL-23 inhibitors
5.8. Health economics studies demonstrating cost effectiveness of IL-23 antagonists in moderate to severe psoriasis management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. IL-23 Receptor Antagonist Market, by Indication
8.1. Introduction
8.2. Crohn's Disease
8.3. Psoriasis
8.4. Psoriatic Arthritis
8.5. Ulcerative Colitis
9. IL-23 Receptor Antagonist Market, by Product
9.1. Introduction
9.2. Guselkumab
9.3. Risankizumab
9.4. Tildrakizumab
10. IL-23 Receptor Antagonist Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Government Hospital
10.2.2. Private Hospital
10.3. Retail Pharmacy
10.3.1. Chain Pharmacy
10.3.2. Independent Pharmacy
10.4. Specialty Pharmacy
11. IL-23 Receptor Antagonist Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous Infusion
11.3. Subcutaneous Injection
12. IL-23 Receptor Antagonist Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line
13. IL-23 Receptor Antagonist Market, by Patient Age Group
13.1. Introduction
13.2. Adults
13.3. Pediatrics
14. Americas IL-23 Receptor Antagonist Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa IL-23 Receptor Antagonist Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific IL-23 Receptor Antagonist Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Janssen Pharmaceutical Companies of Johnson & Johnson
17.3.3. Merck & Co., Inc.
17.3.4. Eli Lilly and Company
17.3.5. Sun Pharmaceutical Industries Limited
17.3.6. Almirall, S.A.
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. IL-23 RECEPTOR ANTAGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IL-23 RECEPTOR ANTAGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IL-23 RECEPTOR ANTAGONIST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. IL-23 RECEPTOR ANTAGONIST MARKET: RESEARCHAI
FIGURE 28. IL-23 RECEPTOR ANTAGONIST MARKET: RESEARCHSTATISTICS
FIGURE 29. IL-23 RECEPTOR ANTAGONIST MARKET: RESEARCHCONTACTS
FIGURE 30. IL-23 RECEPTOR ANTAGONIST MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IL-23 RECEPTOR ANTAGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY GUSELKUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY GUSELKUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY TILDRAKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY GOVERNMENT HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY GOVERNMENT HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 106. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 107. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 110. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 111. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 116. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 117. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. CANADA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 122. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 123. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 126. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. MEXICO IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 204. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 205. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 208. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 209. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 210. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 211. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. GERMANY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 220. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 221. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. FRANCE IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 252. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 253. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 256. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 257. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. ITALY IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 268. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 269. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 272. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 273. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 274. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 275. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 278. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 279. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. SPAIN IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA IL-23 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA IL-23 RECEPTOR ANTAGONIST MARK

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this IL-23 Receptor Antagonist Market report include:
  • AbbVie Inc.
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Limited
  • Almirall, S.A.

Related Topics

Related Reports

IL-12 Receptor Antagonist Market by Indication (Crohn Disease, Psoriasis, Psoriatic Arthritis), Route Of Administration (Intravenous Infusion, Subcutaneous Injection), Distribution Channel, End User, Form, Patient Age Group, Dosage Strength - Global Forecast 2025-2030 - Product Image

IL-12 Receptor Antagonist Market by Indication (Crohn Disease, Psoriasis, Psoriatic Arthritis), Route Of Administration (Intravenous Infusion, Subcutaneous Injection), Distribution Channel, End User, Form, Patient Age Group, Dosage Strength - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
IL-6 Receptor Antagonist Market by Indication (Cytokine Release Syndrome, Juvenile Idiopathic Arthritis, Rheumatoid Arthritis), Route Of Administration (Intravenous Infusion, Subcutaneous Injection), Product Type, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

IL-6 Receptor Antagonist Market by Indication (Cytokine Release Syndrome, Juvenile Idiopathic Arthritis, Rheumatoid Arthritis), Route Of Administration (Intravenous Infusion, Subcutaneous Injection), Product Type, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
IL-1 Receptor Antagonist Market by Indication (Cryopyrin-Associated Periodic Syndromes, Gout, Rheumatoid Arthritis), Route Of Administration (Intraperitoneal, Intravenous, Subcutaneous), Dosage Form, Distribution Channel, End-User, Patient Type - Global Forecast 2025-2030 - Product Image

IL-1 Receptor Antagonist Market by Indication (Cryopyrin-Associated Periodic Syndromes, Gout, Rheumatoid Arthritis), Route Of Administration (Intraperitoneal, Intravenous, Subcutaneous), Dosage Form, Distribution Channel, End-User, Patient Type - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
IL-6 Receptor Antagonist - Pipeline Insight, 2025 - Product Image

IL-6 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Interleukin 8 Receptor Antagonists - Pipeline Insight, 2025 - Product Image

Interleukin 8 Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.